On May 27, 2021, Magenta Therapeutics, Inc. announced that John Davis, its Chief Medical Officer and Head of Research and Development, intends to resign from his position for family reasons. Dr. Davis will remain with the Company as Chief Medical Officer and Head of Research and Development through a transition period that is expected to end no later than July 30, 2021. Following the transition period, Dr. Davis will become a member of Magenta’s Scientific Advisory Board. Dr. Davis’ departure was not related to any disagreements with the Company on any matter relating to its operations, policies, practices or any issues regarding financial disclosures, accounting or legal matters. The Company has commenced a formal search for a new chief medical officer.